---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-098702"
form_type: "8-K"
ticker: "INMB"
cik: "0001711754"
company_name: "Inmune Bio, Inc."
filed_at: "2025-10-14T23:59:59+00:00"
generated_at: "2026-05-17T03:55:01.507505+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# INmune Bio CEO to present at Maxim Growth Summit on RDEB panel

## Summary
- CEO David Moss will participate in a Dermatologic Rare Disease Panel at the Maxim Growth Summit on Oct 22, 2025.
- Panel to discuss CORDStrom platform for Recessive Dystrophic Epidermolysis Bullosa (RDEB) treatment.
- Summit takes place Oct 22-23 at Hard Rock Hotel, NYC; one-on-one meetings available.
- No financial or operational updates provided in this filing.

## SEC filing metadata
- accession: 0001213900-25-098702
- form_type: 8-K
- ticker: INMB
- cik: 0001711754
- company_name: Inmune Bio, Inc.
- filed_at: 2025-10-14T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711754/000121390025098702/0001213900-25-098702-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711754/000121390025098702/ea0260457-8k_inmune.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-098702
- JSON: https://secwatch.observer/filing/0001213900-25-098702.json
- Plain text: https://secwatch.observer/filing/0001213900-25-098702.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.